Sabrina et al. treated melanoma cells with BRAF inhibitors and breast cancer cells with HER2-targeted drugs, which increased the NRP1 expression via JNK-dependent signaling cascade and upregulated the EGFR/IGF1R and mediated adaptive resistance. The gene discussed is NRP1; the disease is breast carcinoma.